A PHASE 1 STUDY OF SAFETY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF TAS1553 IN SUBJECTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) AND OTHER MYELOID NEOPLASMS

Registry ID

TAS1553-01

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ASTEX PHARMACEUTICALS INC.

Start date

2021-06-15

Completion date

2023-02-20

Last update

2020-08-28

Conditions

• ACUTE MYELOID LEUKEMIA
• MYELOID MALIGNANCIES

Related clinical trials

• PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ASSESSING ZIFTOMENIB IN COMBINATION WITH EITHER STANDARD OF CARE NONINTENSIVE (VENETOCLAX+AZACITIDINE) OR INTENSIVE (7+3) THERAPY IN PATIENTS WITH UNTREATED NPM1 MUTATED OR KMT2A REARRANGED ACUTE MYELOID LEUKEMIA
• A PHASE 1 STUDY OF TAK-243 FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES WITH INCREASED BLASTS
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF BLEXIMENIB, VENETOCLAX AND AZACITIDINE FOR THE TREATMENT OF PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA HARBORING KMT2A REARRANGEMENTS OR NPM1 MUTATIONS WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
• A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD NEGATIVE ACUTE MYELOID LEUKEMIA (QUANTUM-WILD)
• A PHASE 1, FIRST IN HUMAN, DOSE ESCALATION STUDY OF JNJ- 89853413 FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYPLASTIC NEOPLASMS
• A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF REVUMENIB IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES

View on source registry